CBP, Polyclonal Antibody

CREBBP; CBP; CREB-binding protein

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Rabbit

CBP Polyclonal Antibody detects endogenous levels of CBP protein.

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

1 mg/ml (lot specific)

Store at -20 degree C/1 year

Small volumes of anti-CBP antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Total protein Ab

Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), ELISA (EIA)

Western Blot: 1:500 - 1:2000
Immunohistochemistry: 1:100 - 1:300
Immunofluorescence: 1:200 - 1:1000
ELISA: 1:20000
Not yet tested in other applications.

Western Blot analysis of HT29 cells using CBP Polyclonal Antibody

Western Blot analysis of AD293 HELA cells using CBP Polyclonal Antibody

260,993 Da

CREB binding protein

CREB-binding protein

CREB-binding protein

CBP  [Similar Products]

CBP_HUMAN

This gene is ubiquitously expressed and is involved in the transcriptional coactivation of many different transcription factors. First isolated as a nuclear protein that binds to cAMP-response element binding protein (CREB), this gene is now known to play critical roles in embryonic development, growth control, and homeostasis by coupling chromatin remodeling to transcription factor recognition. The protein encoded by this gene has intrinsic histone acetyltransferase activity and also acts as a scaffold to stabilize additional protein interactions with the transcription complex. This protein acetylates both histone and non-histone proteins. This protein shares regions of very high sequence similarity with protein p300 in its bromodomain, cysteine-histidine-rich regions, and histone acetyltransferase domain. Mutations in this gene cause Rubinstein-Taybi syndrome (RTS). Chromosomal translocations involving this gene have been associated with acute myeloid leukemia. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Feb 2009]

CBP: a protein acetyltransferase that can transcriptionally activate histones. Acetylates the NCOA3 coactivator. Binds specifically to phosphorylated CREB1 and enhances its transcriptional activity toward cAMP-responsive genes. Methylation of the KIX domain by CARM1 blocks association with CREB, blocking CREB signaling, and activating the apoptotic response. Found in a complex containing NCOA2, NCOA3, IKKA, IKKB, and IKBKG. Probably part of a complex with HIF1A and EP300. Interacts with the C-terminal region of CITED4. The TAZ-type 1 domain interacts with HIF1A. Interacts with MAF, SRCAP, CARM1, ELF3, MLLT7/FOXO4, N4BP2, NCOA1, NCOA3, NCOA6, PCAF, PELP1, PML, SMAD1, SMAD2, SMAD3, SPIB and TRERF1. Interacts with HTLV-1 Tax, p30II, and HIV-1 Tat. Interacts with KLF1; the interaction results in acetylation of KLF1 and enhancement of its transcriptional activity. Interacts with ZCCHC12. Interacts with DAXX; the interaction is dependent on CBP sumoylation and results in suppression of the transcriptional activiy via recruitment of HDAC2 to DAAX. Interacts with MTDH. Interacts with NFATC4. Interacts with MAFG; the interaction acetylates MAFG in the basic region and stimulates NFE2 transcriptional activity through increasing its DNA-binding activity. Interacts with IRF2; the interaction acetylates IRF2 and regulates its activity on the H4 promoter. Interacts via its N-terminus with the C-terminus of SS18L1. Interacts with MECOM. Chromosomal aberrations involving CBP may be a cause of acute myeloid leukemias. Known translocation partners include MYST3, MLL, and MYST4. MYST3-CBP fusion proteins may induce leukemia by inhibiting RUNX1-mediated transcription. Defects in CBP are a cause of Rubinstein-Taybi syndrome type 1 (RSTS1), an autosomal dominant disorder characterized by craniofacial abnormalities, broad thumbs, broad big toes, mental retardation and a propensity for development of malignancies.

Protein type: Motility/polarity/chemotaxis; EC 2.3.1.48; DNA-binding; Nuclear receptor co-regulator; Transcription, coactivator/corepressor; Acetyltransferase

Chromosomal Location of Human Ortholog: 16p13.3

Cellular Component: nucleoplasm; nuclear body; transcription factor complex; nuclear chromatin; cytoplasm; outer kinetochore of condensed chromosome; nucleus; histone acetyltransferase complex

Molecular Function: MRF binding; protein binding; signal transducer activity; histone acetyltransferase activity; zinc ion binding; p53 binding; acetyltransferase activity; transcription coactivator activity; chromatin binding; transcription factor binding; transcription factor activity

Biological Process: transcription initiation from RNA polymerase II promoter; Notch signaling pathway; establishment and/or maintenance of chromatin architecture; viral reproduction; positive regulation of transcription, DNA-dependent; rhythmic process; germ-line stem cell maintenance; negative regulation of transcription from RNA polymerase II promoter; cellular lipid metabolic process; signal transduction; regulation of transcription, DNA-dependent; homeostatic process; response to hypoxia; positive regulation of interferon type I production; innate immune response; positive regulation of transcription from RNA polymerase II promoter; gene expression; protein complex assembly; embryonic digit morphogenesis; histone acetylation; regulation of smoothened signaling pathway; N-terminal peptidyl-lysine acetylation

Disease: Rubinstein-taybi Syndrome 1

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.